% | $
Quotes you view appear here for quick access.

Omeros Corporation Message Board

  • dooper55 dooper55 Apr 18, 2013 11:50 AM Flag

    WBB updated report today. Strong Buy, $20 Price Target

    WBB Securities issued an updated, strongly positive research report on OMER today. Here are the opening paragraphs:

    Replenishing Big Pharma's Pipeline

    As large pharmaceutical companies see their pipelines dwindling, they will need to turn to
    smaller companies with proprietary molecules that can be developed into new therapeutic
    capabilities. In our opinion, Omeros Corporation (OMER) is one company that fulfills such a
    requirement. OMER possesses tremendous resources including: a Phase III product ready for
    launch in 2014 that is expected to be quickly adopted by physicians (OMS 302 for
    ophthalmologic surgery), a Phase III product for arthroscopic knee surgery (OMS103) two
    phosphodiesterase programs (PDE10 for schizophrenia and PDE7 for addiction), plus a library
    of unlocked G protein coupled receptors (GPCRs), which hold the key to development of new
    drugs for life-threatening indications.

    There are close to 120 Orphan GPCRs for which there are no known ligands and OMER has
    demonstrated repeated success using its proprietary high-throughput cellular redistribution
    assay to identify small-molecule agonists, antagonists and inverse agonists.

    OMER's two Phase III products, its two phosphodiesterase products under development and its
    library of ligands that unlock GPCRs (See page 6) are valuable resources and should be
    targets for acquisition or partnering by other pharmaceutical firms. In our opinion, OMER will
    eventually be approached by other companies to gain access to its resources. We are
    therefore reaffirming our Strong Buy recommendation of OMER and continuing our 12-month
    target price of $20.00.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
11.23+0.71(+6.75%)Jul 1 4:00 PMEDT